asenapine
- Generic Name
- asenapine
- Brand Names
- Saphris, Secuado, Sycrest
- Drug Type
- Small Molecule
- Chemical Formula
- C17H16ClNO
- CAS Number
- 65576-45-6
- Unique Ingredient Identifier
- JKZ19V908O
- Background
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as ...
- Indication
适用于成人精神分裂症和双相情感障碍患者的治疗。
- Associated Conditions
- Bipolar 1 Disorder, Mixed manic depressive episode, Schizophrenia, Acute Manic episode
- Associated Therapies
- Maintenance therapy
Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies
Schizophrenia clinical trial pipeline features 55+ companies and 60+ drugs, with key players like Sumitomo Pharma America, Boehringer Ingelheim, and Reviva Pharmaceuticals advancing novel therapies. Recent milestones include Reviva's Phase III RECOVER trial data, Luye Pharma Group's IND approval for LY03020, and Teva's positive SOLARIS trial results. DelveInsight's report provides comprehensive global coverage and insights into the schizophrenia pipeline.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath